Icovamenib is under clinical development by Biomea Fusion and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Icovamenib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Biomea Fusion overview
Biomea Fusion is a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers. The company is headquartered in Palo Alto, California, the US.
For a complete picture of Icovamenib’s drug-specific PTSR and LoA scores, buy the report here.